1605P Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Year: 2024
Type: article
Source: Annals of Oncology
Institutions: Institut Gustave Roussy, Institut Bergonié, Institut Paoli-Calmettes, Centre Léon Bérard, Hôpital Foch, Institut de Cancérologie Strasbourg, Velindre NHS Trust, Beatson West of Scotland Cancer Centre, University of Glasgow, Cardiff University, Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, James Cook University Hospital, University of Manchester, The Christie NHS Foundation Trust, Tampere University Hospital, Orion Corporation (United Kingdom), Orion Corporation (Finland), Merck & Co., Inc., Rahway, NJ, USA (United States), University of Minnesota, Masonic Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, American Society of Clinical Oncology, Celgene, Regeneron Pharmaceuticals, Exelixis, Society for Immunotherapy of Cancer, Menarini Silicon Biosystems, MacroGenics, Seagen, Cancer Research UK, Eisai, Astellas Pharma, Servier, Ipsen, Daiichi Sankyo Europe, Cilag
OpenAlex ID: W4402560230